Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Share-based Compensation (2016 - 2025)

Tandem Diabetes Care's Share-based Compensation history spans 13 years, with the latest figure at $20.1 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 28.6% year-over-year to $20.1 million; the TTM value through Dec 2025 reached $92.4 million, down 8.88%, while the annual FY2025 figure was $92.4 million, 8.88% down from the prior year.
  • Share-based Compensation reached $20.1 million in Q4 2025 per TNDM's latest filing, down from $21.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $28.2 million in Q4 2024 to a low of $12.9 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $21.4 million, with a median of $21.6 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: soared 42.94% in 2022, then dropped 28.6% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $17.1 million in 2021, then soared by 42.94% to $24.4 million in 2022, then dropped by 6.96% to $22.7 million in 2023, then grew by 23.86% to $28.2 million in 2024, then dropped by 28.6% to $20.1 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Share-based Compensation are $20.1 million (Q4 2025), $21.1 million (Q3 2025), and $25.6 million (Q2 2025).